Abbott Laboratories (ABT) Operating Income (2009 - 2026)

Abbott Laboratories has disclosed Operating Income across 18 years of filings, most recently posting $1.7 billion for Q2 2026.

• In Q2 2026, Operating Income fell 17.5% year-over-year to $1.7 billion; the TTM figure through Jun 2026 stood at $7.3 billion (down 2.25% YoY), while the FY2025 annual figure was $8.1 billion, up 17.99% from the prior year.
• Operating Income came in at $1.7 billion for Q2 2026 at Abbott Laboratories, up from $1.3 billion in the prior quarter.
• In the past five years, Operating Income ranged from a high of $2.9 billion in Q1 2022 to a low of $1.3 billion in Q4 2022.
• Average Operating Income over 5 years is $1.8 billion, with a median of $1.7 billion recorded in 2022.
• Year-over-year, Operating Income soared 70.69% in 2022 and tumbled 48.18% in 2023.
• Over 5 years, Operating Income stood at $1.3 billion in 2022, then jumped by 36.5% to $1.8 billion in 2023, then gained by 7.36% to $1.9 billion in 2024, then climbed by 17.79% to $2.3 billion in 2025, then slipped by 24.79% to $1.7 billion in 2026.
• Per Business Quant data, the three most recent Operating Income figures were $1.7 billion in Q2 2026, $1.3 billion in Q1 2026, and $2.3 billion in Q4 2025.